Sur vs Tuvalu: The number of people with susceptibility test result for rifampicin
Sur
97.1
in 2021
Tuvalu
100
in 2021
Sur rank
2nd
Tuvalu rank
2nd
The number of people with susceptibility test result for rifampicin over time
- Sur
- Tuvalu
How they compare
Tuvalu currently reports 100 against 97.1 in Sur, a difference of 2.9.
The two have swapped places 2 times across 5 shared years of data; in 2017 it was Tuvalu ahead.
Sur ranks 2nd and Tuvalu ranks 2nd of 2 regions.
Across the 2 decades both report, Sur averaged higher in 1 and Tuvalu in 1.
Head to head by decade
| Decade | Sur | Tuvalu | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 86.78 | 114.29 | 27.51 | Tuvalu |
| 2020s | 97.8 | 96.88 | 0.9295 | Sur |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Sur or Tuvalu?
- Tuvalu, at 100 against 97.1 in Sur as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Sur and Tuvalu?
- 2.9, with Tuvalu ahead.
- How many years of comparable data are there for Sur and Tuvalu?
- 5 years are reported by both, from 2017 to 2021.
- How do Sur and Tuvalu rank globally for the number of people with susceptibility test result for rifampicin?
- Sur ranks 2nd and Tuvalu ranks 2nd of 2 regions.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid refreshes it automatically from the source and publishes the full history for both places.